Date: Sept 13, 2022 Your Name: Kaj Blennow

Manuscript Title: Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of

Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum

Manuscript number: DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986),	To the institution
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjärnfonden, Sweden (#F02017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for	To the institution

		Neurodegenerative Disorders (JPND2019-466-236), the National Institute of Health (NIH), USA, (grant #1R01AG068398-01), and the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495).	
3	Royalties or licenses	None	
4	Consulting fees	Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Lilly, MagQu, Ono Pharma, Roche Diagnostics, and Siemens Healthineers	To me as an individual.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Novartis, Julius Clinical,	To me as an individual.
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	CSF Society for Clinical Neurochemistry	President (unpaid)
11	Stock or stock options	co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program	Unrelated to the present manuscript
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

13	Other financial or non- financial interests	None	

Please place an "X" next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	9/13/2022
Your Name:	Barbara Bendlin
Manuscript Title:	Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum
Manuscript Number (if known):	DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	R01AG062285, Payment made to institution P30AG062715, Payment made to institution R01AG037639, Payment made to institution ick the tab key to add additional rows. R01AG054059, Payment made to institution	
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None R01AG070883 RF1AG057784 R01AG059312 R01AG070973	Payment made to institution Payment made to institution Payment made to institution Payment made to institution

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	□ None Monetary Award Trust Account, held by the NFL Players' Concussion Injury Litigation Settlement Trust	Payment made to me.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Mone Honorarium from UC-Irvine for lecture. Honorarium from University of Pittsburgh for presentation. Honorarium for lecture at Karolinska Institutet Honorarium for lecture at University of Illinois	Payment made to me.
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None Alzheimer's Association Support for attendance at AAIC	Payment made to me.
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	✓ None Weston Advisor Grant for service on Weston Advisory Board	Payment made to institution.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Chair, ADRC research education committee national committee. CLSA-Healthy Brains Healthy Aging/Weston Advisory committee Rush ADRC external advisory board	Unpaid Unpaid Unpaid
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	9/21/2022
Your Name:	Sterling Johnson
Manuscript Title:	Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum
Manuscript Number (if known):	DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as need	Specifications/Comments (e.g., if payments were ed) made to you or to your institution)
		Time frame: Since the initial plan	ning of the work
1	All support for the present manuscript (e.g.,	□ None	
	funding, provision of study materials,	NIH R01AG027161, NIH RO1AG021155	Grant to Institution
	medical writing, article processing charges, etc.) No time limit for this item.	Cerveau Technologies	Grant to Institution Click the tab key to add additional rows.
		Time frame: past 36 m	onths
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	□ None	
		Roche Diagnostics Eisai	Payment to individual Payment to individual
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None Non	
10	Leadership or fiduciary role in other board,	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid	Past chair of the national ADRC Imaging core Steering committee	
11	Stock or stock options	None None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None Equipment grant from Roche Diagnostics	To institution
13	Other financial or non-financial interests	None None	
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	9/13/2022
Your Name:	Andrew L Alexander
Manuscript Title:	Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum
Manuscript Number (if known):	DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Click the tab key to add additional rows.	
		Time frame: past 36 mont	hs
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None Non	
8	Patents planned, issued or pending	None Non	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board,	None ■	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or			
	advocacy group, paid or unpaid			
11	Stock or stock options	\boxtimes	None	
12	Receipt of equipment,		None	
	materials, drugs, medical writing,			
	gifts or other			
	services			
13	Other financial or non-financial		None	
	interests			
Plea	Please place an "X" next to the following statement to indicate your agreement:			
\boxtimes	I certify that I have answered every question and have not altered the wording of any of the questions on this form			

Date:	2022-09-13	
Your Name	: _Henrik Zetterberg	
Manuscript	: Title: Associations Between	Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's
Disease Pat	thology and Neurodegenerat	on along the Alzheimer's Disease Continuum
Manuscript	number (if known): DADM-	0-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if	cations/Comments payments were made or to your institution)
		Time frame: Since the initial plans	ning of th	ne work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing. None HZ is a Wallenberg Scholar supported by a from the Swedish Research Council (#201 02532), the European Union's Horizon European Union's H	8- rope er grant Support ne DDF), c Fund 1- F-21-	Payments made to Institution.	
	article processing	831377-C), the Bluefield Project, the Olav Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarin Hjärnfonden, Sweden (#FO2022-0270), th European Union's Horizon 2020 research	nor, ne	

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
charges, etc.) No time limit for this item.	innovation programme under the Marie Skłodowska-Curie grant agreement No 86 (MIRIADE), the European Union Joint Prog – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003).	gramme
		Click the tab key to add additional rows
	Time frame: past 36 mg	onths
2 Grants or contracts from any entity (if not indicated in item #1 above).	HZ is a Wallenberg Scholar support by grants from the Swedish Resection (#2018-02532), the European Europe research innovation programme under grangreement No 101053962, Swed State Support for Clinical Researce (#ALFGBG-71320), the Alzheime Discovery Foundation (ADDF), U (#201809-2016862), the AD Straffund and the Alzheimer's Associate (#ADSF-21-831376-C, #ADSF-21-831376-C, and #ADSF-21-831376-C, #ADSF	earch opean n and ant lish ch er Drug (SA ategic ation L- (7-C), non Family en Union's vation ent No n

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)		payments were made
3	Royalties or licenses	None ■		
4	Consulting fees	HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave.		Payments made to HZ.
5	Payment or honoraria for lectures, presentati ons, speakers bureaus, manuscrip t writing or education al events	HZ has given lectures in symposi sponsored by Fujirebio, Alzecure Cellectricon, Biogen, and Roche.		Payments made to HZ.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	None ■	
9	Participati on on a Data Safety Monitorin g Board or Advisory Board	HZ has served at scientific advisor boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath Annexon, Apellis, Artery Therapeth AZTherapies, CogRx, Denali, Eisan Nervgen, Novo Nordisk, Passage Pinteon Therapeutics, Red Abbey reMYND, Roche, Samumed, Siem Healthineers, Triplet Therapeutics, Wave.	r h, eutics, i, Bio, v Labs, ens
1 0	Leadership or fiduciary role in other board, society,	□ None HZ is chair of the Alzheimer's Association Global Biomarker Standardization Consortium.	No payments made.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	committee or advocacy group, paid or unpaid			
1 1	Stock or stock options	HZ is a co-founder of Brain Bioma Solutions in Gothenburg AB (BBS) which is a part of the GU Venture Incubator Program.),	
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None ■		
1 3	Other financial or non-financial interests	None ■		
ag	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	9/15/2022
Your Name:	Steven R Kecskemeti
Manuscript Title:	Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum
Manuscript Number (if known):	DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Technical development (acquisition and analysis) Manuscript guidance Click the tab key to add additional rows.	
		Time frame: past 36 month	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None Non	
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board,	None ■	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or			
	advocacy group, paid or unpaid			
11	Stock or stock options	\boxtimes	None	
12	Receipt of equipment,		None	
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-financial		None	
	interests			
Plea	Please place an "X" next to the following statement to indicate your agreement:			
\boxtimes	I certify that I have answered every question and have not altered the wording of any of the questions on this form			

Date:	9/13/2022
Your Name:	Douglas C Dean III
Manuscript Title:	Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum
Manuscript Number (if known):	DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	g of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Click the tab key to add additional rows.	
		Time frame: past 36 mont	hs
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None Non	
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board,	None ■	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or			
	advocacy group, paid or unpaid			
11	Stock or stock options	\boxtimes	None	
12	Receipt of equipment,		None	
	materials, drugs, medical writing,			
	gifts or other			
	services			
13	Other financial or non-financial		None	
	interests			
Plea	Please place an "X" next to the following statement to indicate your agreement:			
\boxtimes	I certify that I have answered every question and have not altered the wording of any of the questions on this form			

Date:	9/16/2022
Your Name:	Cynthia Carlsson
Manuscript Title:	Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum
Manuscript Number (if known):	DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	✓ None Click the tab key to add additional rows.	
		Time frame: past 36 month	s
2	Grants or contracts from	□ None	
	any entity (if not	NIH/Lilly grant support for A4 study	Grant funding to university
	indicated in item	NIH/Esai grant support for AHEAD study	Grant funding to university
	#1 above).	VA Merit Grant for BRAVE study	Grant funding to VA
		NIH for PREVENTABLE study funding	Grant funding to VA
		Amarin Corp for study drug (Vascepa/placebo) for VA BRAVE study	Study medications for VA study

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None ■ None None	
7	Support for attending meetings and/or travel	□ None Clinical Trials in Alzheimer's Disease travel 2021 (paid by meeting organizers)	Travel reimbursement paid to me by meeting organizers
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None NIH DSMB for Univ Kansas TCAD study (R01) Alzheimer's Assoc DSMB for US Pointer study NIH DSMB for UCLA D-CARE Study	No honorarium No honorarium Honorarium to me
10	Leadership or fiduciary role in other board,	⊠ None	

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
society, committee or advocacy group, paid or unpaid	Chair, US Health and Human Services Advisory Council for Alzheimer's Research, Care, and Support Services (NAPA council) Co-Chair, NIH Clinical Task Force Clinical and	Travel covered for face-to-face meetings by HHS One-time honorarium to me
	Diagnostic Measures subcommittee Advisory Committee, NIA Beeson Annual Meeting Chair, NIA Beeson Emerging Leaders study section	Honorarium to me Travel costs and stipend to me
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical writing, gifts or other services	None ■	
Other financial or non-financial interests	None	
	committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-financial	Society, committee or advocacy group, paid or unpaid Co-Chair, NIH Clinical Task Force Clinical and Diagnostic Measures subcommittee Advisory Committee, NIA Beeson Annual Meeting Chair, NIA Beeson Emerging Leaders study section Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-financial

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	9/13/2022
Your Name:	Norbert Wild
Manuscript Title:	Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum
Manuscript Number (if known):	DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Roche Diagnostics GmbH NW receives a salary as a full time employee from Roc Click the tab key to add additional rows.	che Diagnostics GmbH.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	None Non	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None ■	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	□ None Full-time employee of Roche Diagnostics GmbH, Penzberg, Germany	
Pleas		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	9/13/2022
Your Name:	Gwendlyn Kollmorgen
Manuscript Title:	Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum
Manuscript Number (if known):	DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Roche Diagnostics GmbH GK receives a salary as a full time employee from Roc Click the tab key to add additional rows.	che Diagnostics GmbH.
		Time frame: past 36 months	5
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	None Non	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None ■	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	□ None Full-time employee of Roche Diagnostics GmbH, Penzberg, Germany	
Pleas		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	9/13/2022
Your Name:	Ivonne Suridjan
Manuscript Title:	Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum
Manuscript Number (if known):	DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Roche Diagnostics IS receives a salary as a full time employee from Roche Diagnostics. Click the tab key to add additional rows.	
		Time frame: past 36 month:	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	None Non	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None Non	
13	Other financial or non-financial interests	□ None Full-time employee of Roche Diagnostics International Ltd.	
Pleas		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	9/12/2022
Your Name:	Jason Moody
Manuscript Title:	Associations Between Diffusion MRI Microstructure and Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Neurodegeneration along the Alzheimer's Disease Continuum
Manuscript Number (if known):	DADM-D-22-00061R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present	□ None	
	manuscript (e.g., funding, provision of study materials,	National Institute of General Medical Sciences (NIH/NIGMS) - Initiative for Maximizing Student Development (IMSD – Grant No. R25 GM083252)	
	medical writing, article processing	Biology of Aging and Age-Related Diseases Training Grant (Grant No. T32 AG000213)	
	charges, etc.) No time limit for this item.	SciMed Graduate Research Scholars Fellowship	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None Non	
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board,	None ■	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid			
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Please place an "X" next to the following statement to indicate your agreement:				
\boxtimes	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

3 8/26/2021 ICMJE Disclosure Form